Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Phase 1positiveAGMB-447Positive

AI Analysis

Summary

Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and outlined plans for the Phase 2 INSPIRIA study.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Positive Phase 1 results reported

Importance:5/10

Sentiment:

0.80

Phase 1IPFPulmonary FibrosisClinical TrialPositive Results

Read the original article

Published by GlobeNewswire Clinical Studies on September 14, 2026 8:05 PM

Read Original